Anti-Glial Fibrillary Acidic Protein (GFAP) eFluor® 615

Description: This GA5 monoclonal antibody reacts with human, mouse, rat, chicken, rabbit, and pig glial fibrillary acidic protein (GFAP). This 49-kDa type III intermediate filament protein is expressed in neural tissues and distinguishes astrocytes from other glial cells during central nervous system development. Three alternative splice variants of GFAP exist; however, \alpha-GFAP is the predominant form expressed in astrocytes. GFAP can co-assemble with vimentin and nestin in astrocytes, but such associations are not required for assembly. Like other intermediate filaments, GFAP assembly is dependent on phosphorylation and dephosphorylation of the N-terminal domain. Studies have demonstrated that mutations in the GFAP gene lead to Alexander disease. Moreover, GFAP has also been shown to be overexpressed in certain glial-derived tumors.

References: Quinlan RA, Brenner M, Goldman JE, Messing A. GFAP and its role in Alexander disease. Exp Cell Res. 2007 Jun 10;313(10):2077-87.

McLendon RE, Bigner DD. Immunohistochemistry of the glial fibrillary acidic protein: basic and applied considerations. Brain Pathol. 1994 Jul;4(3):221-8.

Mokuno K, Kamholz J, Behrman T, Black C, Sessa M, Feinstein D, Lee V, Pleasure D. Neuronal modulation of Schwann cell glial fibrillary acidic protein (GFAP). J Neurosci Res. 1989 Aug;23(4):396-405. (GA5, WB)

Rasmussen S, Bock E, Warecka K, Althage G. Quantitation of glial fibrillary acidic protein in human brain tumours. Br J Cancer. 1980 Jan;41(1):113-6.